AMD vs OCGN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AMD is the larger of the two ($853.44B market cap): the incumbent the market prices for continued execution (29.42x forward earnings, beta 2.54). OCGN is the smaller challenger ($328.35M), priced similarly on forward earnings (-3.82x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
AMD vs OCGN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AMD | OCGN | What it tells you |
|---|---|---|---|
| Market cap | $853.44B | $328.35M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 29.42 | -3.82 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 2.54 | 1.98 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 71% of range | 14% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how AMD and OCGN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMD and OCGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMD and OCGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Advanced Micro Devices (AMD) do?
Advanced Micro Devices (AMD) designs CPUs, GPUs, and adaptive computing chips. The company has two main client-facing CPU lines: Ryzen for consumer PCs and EPYC for data center servers. EPYC has gained significant share against Intel Xeon in cloud and enterprise data centers over the past five years. The Instinct GPU line (MI300X, MI325X, MI350, and the MI400 family including the MI450 and MI455X) is AMD's AI accelerator platform and the primary direct competitor to NVIDIA's data center GPUs, now sold as full Helios rack-scale systems as well as individual chips.
What does Ocugen (OCGN) do?
Ocugen, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on gene and cell therapies for eye diseases. Its core asset is a modifier gene-therapy platform that uses nuclear hormone receptor genes to address disease across many genetic mutations rather than one at a time. The lead program, OCU400, targets broad retinitis pigmentosa in the Phase 3 liMeliGhT trial; OCU410 targets geographic atrophy secondary to dry age-related macular degeneration; and OCU410ST targets Stargardt disease. The company has framed a goal of pursuing three biologics license applications across these programs, with the first, for OCU400, now planned for the second quarter of 2027 after Phase 3 topline data in the first quarter, and also runs earlier-stage work in other modalities.
AMD vs OCGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AMD drivers: Instinct AI GPU and Helios rack ramp; EPYC server share gains.
- OCGN drivers: Lead program advancing toward a regulatory decision; A platform, not a single shot on goal.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: NVIDIA's structural advantages in AI (CUDA ecosystem, manufacturing capacity allocations from TSMC, customer relationships) make AI GPU share gains harder than the hardware comparison alone suggests. For OCGN, ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval.
AMD or OCGN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMD if you believe its drivers more; OCGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMD and OCGN guides.
AMD vs OCGN: the full fundamentals
AMD. AMD's trailing P/E of about 139x looks extreme because GAAP earnings still carry Xilinx amortization and have not caught up with the AI order book; on forward estimates the multiple is about 34x. The gap between the two is the thesis in numbers: the price assumes revenue roughly doubles to about $89 billion in 2027 on MI450 and Helios shipments, so any slip in that ramp would show up quickly in a stock that already moves 3% on a sector rotation day.
OCGN. Ocugen is pre-profit and has no product revenue, so traditional earnings metrics do not apply; what matters is cash runway versus burn. Cash of ~$100 million at June 30, 2026 followed the 2026 convertible note offering, which management said would extend the runway into 2028, while trailing operating cash outflow ran ~$61 million and the second-quarter loss widened to ~$24.9 million. Analysts expect a loss of about $0.05 per share for the third quarter, with results expected around November 5, 2026. Figures are approximate and can move materially with new raises or spending changes.
Headline figures (approximate, October 2026): AMD shows revenue (ttm) ~$41 billion (June 2026 quarter up ~50% YoY), gross / operating margin ~56% / ~17% (GAAP, trailing), net income (ttm) ~$6.5 billion (GAAP; higher non-GAAP), eps (ttm) ~$3.92 GAAP; OCGN shows market capitalization ~$273 million at ~$0.80 per share (Oct 16, 2026), shares outstanding ~339 million, revenue (ttm, collaboration/other) ~$4.6 million, net loss (ttm) ~$81.8 million (~$0.26 per share).
The bottom line: AMD vs OCGN
AMD and OCGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMD and OCGN exposure against your real portfolio. It is not an investment adviser.
Wondering how AMD or OCGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Advanced Micro Devices
Ask Walnut's AI anything about AMD and see how it fits what you own.
FAQ
What is the difference between AMD and OCGN?
+
Advanced Micro Devices (AMD) designs CPUs, GPUs, and adaptive computing chips. Ocugen, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMD or OCGN the better stock?
+
Neither is universally better. AMD is the larger incumbent; OCGN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AMD or OCGN?
+
On forward P/E (as of November 2026), AMD trades at 29.42x and OCGN at -3.82x, so OCGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AMD and OCGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AMD vs OCGN?
+
AMD: NVIDIA's structural advantages in AI (CUDA ecosystem, manufacturing capacity allocations from TSMC, customer relationships) make AI GPU share gains harder than the hardware comparison alone suggests. Expectations are now the larger risk: the shares trade near 139x trailing GAAP earnings and about 34x forward, and consensus assumes EPS roughly doubles from about $7.59 in 2026 to about $15.76 in 2027, which requires the MI450 and Helios ramp to land on schedule. The stock fell from a 52-week high near $659 to about $543 by mid-October 2026 as chip stocks posted eight straight down days amid a rotation out of AI hardware. The World Labs deal adds share dilution and integration work. Intel's eventual recovery in server CPUs is a multi-year risk. OCGN: Ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval. The company funds itself from a limited cash balance and recurring capital raises, and it has historically issued equity and convertible debt that dilute existing shareholders. It competes with larger, better-funded gene-therapy and ophthalmology developers. A single negative readout or regulatory setback could sharply reduce the stock's value. Two newer risks apply as of October 2026. The shares closed at ~$0.80 on October 16, below Nasdaq's $1.00 minimum bid requirement, and a sustained period under that level can trigger a deficiency notice and, if not cured, a reverse split or delisting. The U.S. BLA timeline has also moved out, from a rolling filing guided for the third quarter of 2026 to a planned submission in the second quarter of 2027, which lengthens the period the company must fund before any U.S. approval decision.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMD or OCGN; figures are approximate and dated (as of November 2026). Verify current data before investing.